EBS peer analysis
Emergent BioSolutions (EBS) against its competitors: price, today's move, 1-year return and market value side by side.
EBS and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| AQST Aquestive Therapeutics | $3.79 | 0.53% | -44.43% | $473.18M |
| CMPS COMPASS Pathways | $8.69 | 3.33% | 37.50% | – |
| CRVS Corvus Pharmaceuticals | $9.83 | 1.34% | 22.26% | $815.97M |
| OLMA Olema Pharmaceuticals | $7.37 | 4.17% | -17.89% | – |
| ORGO Organogenesis | $0.76 | -1.64% | -82.22% | $97.21M |
| PRTA Prothena | $8.22 | -0.84% | -23.53% | $425.58M |
| RIGL Rigel Pharmaceuticals | $48.88 | -3.27% | 54.78% | $943.89M |
| SIGA SIGA Technologies | $3.12 | 5.76% | -62.32% | $211.96M |
| SNDL SNDL | $1.34 | 5.91% | -37.44% | $310.87M |
| EBS Emergent BioSolutions | $6.25 | -3.03% | -49.96% | $330.20M |
- EBS's peers: AQST (Aquestive Therapeutics), CMPS (COMPASS Pathways), CRVS (Corvus Pharmaceuticals), OLMA (Olema Pharmaceuticals), ORGO (Organogenesis), PRTA (Prothena), RIGL (Rigel Pharmaceuticals), SIGA (SIGA Technologies).
Updated 2026-11-03 23:15 UTC